Provided by Tiger Trade Technology Pte. Ltd.

First Trust Nasdaq Pharmaceuticals ETF

40.72
+0.25340.63%
Volume:9K
Turnover:379.04K
Market Cap:1.05B
PE:- -
High:40.89
Open:40.73
Low:40.57
Close:40.47
52wk High:42.87
52wk Low:27.30
Shares:25.75M
Float Shares:25.75M
Volume Ratio:0.34
T/O Rate:0.04%
Dividend:0.42
Dividend Rate:1.04%
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

Bristol-Myers Squibb is Maintained at Hold by HSBC

Dow Jones
·
Sep 10

Eli Lilly is Maintained at Reduce by HSBC

Dow Jones
·
Sep 10

Eli Lilly’s GLP-1 Windfall to Fund Push into Women’s Health - Bloomberg News

Reuters
·
Sep 10

AbbVie Says Atogepant Met Primary, Secondary Endpoints in Phase 3 Menstrual Migraine Study

MT Newswires Live
·
Sep 10

AbbVie’s atogepant shows positive Phase 3 results in menstrual migraine

TIPRANKS
·
Sep 10

Abbvie - Atogepant Safety Results Consistent with Known Profile; no New Safety Signals

THOMSON REUTERS
·
Sep 10

Abbvie - Atogepant Meets Primary and All Eight Ranked Secondary Endpoints in Phase 3 Luna Study

THOMSON REUTERS
·
Sep 10

Abbvie Extends Migraine Leadership with Positive Phase 3 Atogepant Results in Menstrual Migraine

THOMSON REUTERS
·
Sep 10

Abbvie - Atogepant Shows Significant Improvements Across Multiple Endpoints Versus Placebo

THOMSON REUTERS
·
Sep 10

Johnson & Johnson receives CE Marking for ACUVUE OASYS MAX

TIPRANKS
·
Sep 10

Johnson & Johnson Receives Ce Marking for Acuvue Oasys Max Reusable Contact Lenses

THOMSON REUTERS
·
Sep 10

Bloomsbury Executives Adjust Holdings After 2023 Share Plan Vesting

TIPRANKS
·
Sep 10

HSBC Adjusts Price Target on Eli Lilly and Co. to $940 From $850, Keeps Reduce Rating

MT Newswires Live
·
Sep 10

Merck Price Target Raised to $161.00/Share from $127.00 by Leerink Partners

Dow Jones
·
Sep 10

Analysts Have Conflicting Sentiments on These Healthcare Companies: Bristol-Myers Squibb (BMY), Stryker (SYK) and InnovAge Holding (INNV)

TIPRANKS
·
Sep 09

Tyra Biosciences Stock Plunges 22% as Bladder Cancer Pill Fails to Impress

Dow Jones
·
Sep 09

Abbvie Exec Says Strong Balance Sheet and Long Growth Runway Allow Company to Consider Both Early- and Late-Stage Business Development Opportunities - Conf Call

THOMSON REUTERS
·
Sep 09

Abbvie Exec Says Expects Approval of Subcutaneous Crohn's Disease Treatment in Q4 - Conf Call

THOMSON REUTERS
·
Sep 09

Leerink Partners Adjusts Price Target on Merck & Co. to $161 From $127, Keeps Outperform Rating

MT Newswires Live
·
Sep 09

Merck & Co Inc : Leerink Partners Raises Target Price to $161 from $127

THOMSON REUTERS
·
Sep 09